Navigation Links
Pilot Study Finds Adding Topical Imiquimod To Laser Therapy Improves The Response Of Port Wine Stain Birthmarks
Date:11/18/2008

n experienced a better and statistically significant degree of fading over time as compared to test sites that received PDL therapy alone or Imiquimod alone. For the test sites receiving Imiquimod therapy alone, no drug-induced fading of port wine stains was observed.

Researchers reported that the enhanced fading obtained on the port wine stain test sites treated with PDL and Imiquimod was maintained up to 12 months following laser therapy. In addition, the combined therapy was found to be safe with only minor side effects which resolved in all patients without medical intervention.

"While more clinical trials need to be conducted to confirm these results, we are encouraged by these early findings and expect that future studies using different dosing measurements of Imiquimod or more frequent application of the drug could further enhance patient outcomes," said Dr. Mihm. "Since all tumors rely on blood vessel growth, the implications of this study are further evidence of the importance of anti-angiogenesis in inhibiting the growth of other types of tumors, even cancerous tumors, with this therapy."
Although the favorable results using PDL and Imiquimod for fading of port wine stain birthmarks were only studied in Asian patients, study collaborator J. Stuart Nelson, MD, PhD, professor of surgery and biomedical engineering at the Beckman Laser Institute and Medical Clinic, University of California, Irvine, in Irvine, Calif., added that similar results would be expected in patients of any ethnic background.
    
"Generally, Asians and other patients with darker skin types do not respond as well to PDL therapy as Caucasians and other patients with lighter skin types," said Dr. Nelson. "The fact that the Asian patients in this study experienced such favorable results in the fading of their port wine stains with this combined therapy is extremely encouraging for the future treatmen
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
2. POET Announces That Cellulosic Ethanol Pilot Facility Will Be Operational This Year
3. Start of First Fingertip Payment Pilot in the Netherlands
4. Applied Isotope Technologies will Exclusively Supply Biochemimarker(TM) Discovery Products for a Unique Pilot Study on Autism
5. IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone
6. Pharsight Welcomes Newest Japanese PKS, AutoPilot Customer
7. FrontPath Health Coalition To Lead Community-wide Group in Pilot Program
8. Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer
9. Masada Resource Group Donates TVA Biomass Pilot Plant Facilities and Equipment to Auburn University
10. Pilot Therapeutics Announces New Executive Team with Extensive Experience Creating New Health and Nutrition Businesses
11. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):From fruit fly wings to heart failure -- why Not(ch)? 2IGC scientist receives prestigious EMBO installation grant 2Uniform analyses for clean drinking water in Europe 2Latest analysis confirms suboptimal vitamin D levels in millions of US children 10517 1Latest analysis confirms suboptimal vitamin D levels in millions of US children 10517 2Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 1Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 2Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 3Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 4Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 5Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 6Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 7Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Gly 60041 8UC San Diego researchers reverse pulmonary arterial hypertension in mouse models 60038 1UC San Diego researchers reverse pulmonary arterial hypertension in mouse models 60038 2